Indian pharmaceutical manufacturer Ranbaxy announced yesterday the launch of two new co-packaged triple combinations of d4T, 3TC and efavirenz, and AZT, 3TC and efavirenz. The company says that the co-packaging is designed to make the drugs easier to take, and each pack contains pictorial instructions on when to take the medication.

• Virolis-E is a `compliance pack` containing two fixed dose combination tablets of lamivudine (3TC) 150mg and stavudine (d4T) 30/40mg and one tablet of efavirenz 600mg.

• Virocomb-E is also a compliance pack and contains two fixed dose combination tablets of lamivudine (3TC) 150mg and zidovudine (AZT) 300mg and one tablet of efavirenz 600mg.

In most countries outside India, these products will be labeled and sold under the Coviro-E and Avocomb-E brand names respectively.

These products have not yet received pre-approval from the World Health Organization or tentative approval by the US Food and Drug Administration.

Efavirenz originators Merck and Bristol Myers Squibb are working with Gilead Sciences to coformulate efavirenz with tenofovir and emtricitabine (FTC) into one tablet, but the effort is proving challenging because of the large quantity of drug that must be pressed into tablets (the total daily dose of the three once-daily drugs amounts to 1100mg of drug).

aidsmap resources

latest news

• Drug-resistant TB now at record levels, says WHO
• Weight gain after starting ART predicts survival
• Aciclovir shows lower efficacy outside US in global trial
• `Test and treat` prevention approach may not require universal treatment to succeed
• Over a third of TB cases in UK prisons are drug-resistant
• High prevalence of drug-resistant TB amongst HIV patients in South Africa
• Genital ulcers frequently associated with HIV shedding in men
• HIV biggest cause of adolescent death, hospitalisation in Zimbabwe
• Visa refusal shines spotlight on China's HIV travel ban
• Rates of new HIV diagnoses amongst US gay men 44 times greater than those in other populations